← Home
Olin
-7.2%
Chemicals / Chemicals and Materials Manufacturing
📢 Press Releases
| Date | Press release |
|---|---|
| 2026-04-02 16:05:00 | Olin Corporation First Quarter 2026 Earnings Conference Call Announcement Clayton, mo., april 2, 2026 /prnewswire/ -- olin corporation (nyse: oln) announced today that on friday, may 8, 2026, at 9:00 a.m. |
| 2026-03-30 20:00:00 | Innovent’s Partner Ollin Biosciences Announces Final Data From Randomized Head-to-head Study Of Ibi324 Compared To Faricimab (vabysmo) In Wet Age-related Macular Degeneration And Diabetic Macular Edema Oln324 demonstrated meaningfully faster and greater improvements in anatomic outcomes in dme and numerically greater vision gains sustained through 20 weeks with fewer retreatments as compared to faricimab new anatomic data demonstrates oln324 achieves faster, greater, and more durable reductions in wamd pigment epithelial detachment (ped) thickness versus faricimab ollin and innovent biologics adva ncing oln324 into global phase 3 studies in dme and wamd in 2026 san francisco and suzhou, china, march 30, 2026 /prnewswire/ -- innovent biologics, inc. (’innovent’) (hkex: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major disease areas, today announced that the company’s partner ollin reported final, 20-week study completion data from its randomized, head-to-head phase 1b jade clinical study comparing oln324(innovent r&d code ibi324) , a higher-potency, smaller-format, higher-molar dose vegf/ang2 bispecific antibody, to faricimab (vabysmo®), in patients with diabetic macular edema (dme) or wet (neovascular) age-related macular degeneration (wamd). final results released include favorable durability data for oln324 compared to faricimab and new anatomic data showing faster, greater, and more durable control of wamd pigment epithelial detachments (peds) with oln324. |
| 2026-02-12 16:05:00 | Olin To Take A Fourth Quarter 2025 Charge Following Verdict In Shintech V. Olin Litigation Clayton, mo., feb. 12, 2026 /prnewswire/ -- olin corporation (nyse: oln), a leading global manufacturer and distributor of chemical products, today issued an update following a recent verdict in a litigation matter filed by shintech incorporated (’shintech’) against olin corporation and its wholly owned subsidiary, blue cube operations llc (collectively, ’olin’). |
| 2026-01-29 16:05:00 | Olin Announces Fourth Quarter 2025 Results Highlights fourth quarter 2025 net loss of ($85.7) million, or ($0.75) per diluted share quarterly adjusted ebitda of $67.7 million year-end 2025 net debt comparable to year-end 2024 clayton, mo., jan. 29, 2026 /prnewswire/ -- olin corporation (nyse: oln) announced financial results for the fourth quarter ended december 31, 2025. |
| 2026-01-08 19:00:00 | Innovent’s Partner Ollin Biosciences Announces Positive Topline Data With Superior Outcomes From A Randomized Head-to-head Study Of Ibi324 Compared To Faricimab (vabysmo®) In Diabetic Macular Edema And Wet Age-related Macular Degeneration San francisco and suzhou, china, jan. 8, 2026 /prnewswire/ -- innovent biologics, inc. (’innovent’) (hkex: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major disease areas, today announced that the company’s partner ollin reported positive topline results from its randomized, head-to-head phase 1b jade clinical study comparing ibi324 (ollin r&d code:oln324), a next-generation vegf/ang2 bispecific antibody, to faricimab (vabysmo®), in over 160 patients with diabetic macular edema (dme) or wet (neovascular) age-related macular degeneration (wamd). oln324’s up to 60-fold higher anti-ang2 potency together with a smaller protein format and a higher molar dose gives oln324 a differentiated, first-line standard of care profile. |
| 2026-01-08 16:05:00 |
|
| 2026-01-06 16:05:00 |
|
| 2025-11-11 08:03:00 |
|
| 2025-10-27 16:05:00 |
|
| 2025-09-26 16:05:00 |
|
| 2025-09-19 08:00:00 |
|
| 2025-09-18 00:00:00 |
|
| 2025-08-19 07:00:00 |
|
| 2025-07-28 16:05:00 |
|
| 2025-06-30 16:05:00 |
|
📰 Browse additional press releases for Olin!
Sign up for free or log in💡 Learn smarter stock picks with "The Checklist Value Investor — A Smarter Way to Pick Stocks"